Literature DB >> 6883809

Association of rheumatoid factor with complement activation in rheumatoid arthritis and other diseases.

P A Reyes, J G Maluf, J G Curd, J H Vaughan.   

Abstract

Rheumatoid factor (RF) is a complement activating autoantibody. In rheumatoid arthritis (RA) the rate of catabolism of complement is closely related to the titre of RF. Therefore, we have examined whether these relationships are unique to RA or will be found in non-RA disorders in which RF may be found in the circulation. We studied patients with subacute bacterial endocarditis, leprosy, tuberculosis, and a variety of other rheumatic and vasculitic disorders. We found that in all the disorders examined the RF had a complement activating potential which was equivalent to that of the RF of RA patients. Furthermore in vivo activation of complement, as exhibited by the appearance of C3 degradation products, was significantly related to higher titres of haemolytically active RF in non-RA as well as the RA group. In these respects, therefore, the RF in RA and non-RA patients is indistinguishable. A possible survival value for RF is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883809      PMCID: PMC1535680     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

1.  On the distribution of rheumatoid factors among the immunoglobulins.

Authors:  R Heimer; F M Levin
Journal:  Immunochemistry       Date:  1966-01

2.  Characterization of the gamma-globulin complexes present in certain sera having high titers of anti-gamma-globulin activity.

Authors:  R E Schrohenloher
Journal:  J Clin Invest       Date:  1966-04       Impact factor: 14.808

3.  Activation of the fourth component of complement (C4): assessment by rocket immunoelectrophoresis and correlation with the metabolism of C4.

Authors:  H Milgrom; J G Curd; R A Kaplan; H J Müller-Eberhard; J H Vaughan
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

4.  Detection of complement activation by counterimmunoelectrophoresis (CIE).

Authors:  C M Arroyave; E M Tan
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

5.  Differential effects of propranolol on lymphocyte rosette formation and response to plant mitogens.

Authors:  J V Dunne; C J Peters; T L Moore; J H Vaughan
Journal:  Arthritis Rheum       Date:  1978 Sep-Oct

6.  Metabolism of C4 and factor B in rheumatoid arthritis. Relation to rheumatoid factor.

Authors:  R A Kaplan; J G Curd; D H Deheer; D A Carson; M K Pangburn; H J Müller-Eberhard; J H Vaughan
Journal:  Arthritis Rheum       Date:  1980-08

7.  Immunoglobulin E-rheumatoid factor in the serum of patients with rheumatoid arthritis, asthma, and other diseases.

Authors:  B L Zuraw; C H O'Hair; J H Vaughan; D A Mathison; J G Curd; D H Katz
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

8.  Complement fixation by rheumatoid factor.

Authors:  K Tanimoto; N R Cooper; J S Johnson; J H Vaughan
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

9.  In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects.

Authors:  L Slaughter; D A Carson; F C Jensen; T L Holbrook; J H Vaughan
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  Complement fixation by a two-component antibody system: immunoglobulin G and immunoglobulin M anti-globulin (rheumatoid factor). Parodoxical effect related to immunoglobulin G concentration.

Authors:  F R Schmid; I M Roitt; M J Rocha
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  7 in total

1.  Interaction of the terminal complement components C5b-9 with synovial fibroblasts: binding to the membrane surface leads to increased levels in collagenase-specific mRNA.

Authors:  B Jahn; J Von Kempis; K L Krämer; S Filsinger; G M Hänsch
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

2.  Enzyme immunoassay of complement-binding rheumatoid factors.

Authors:  A M Teppo; C P Maury
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

3.  Precipitation of 19S IgM rheumatoid factor-IgG circulating immune complexes in patients with juvenile arthritis by polyethylene glycol and separation by immobilized protein A.

Authors:  T L Moore; R W Dorner; P W Sheridan; J Zuckner
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

4.  Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies.

Authors:  A E Bedwell; C J Elson; S D Carter; P A Dieppe; C W Hutton; R Czudek
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

5.  Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy.

Authors:  M Doherty; N Richards; J Hornby; R Powell
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

6.  Enterococcal endocarditis associated with crescentic glomerulonephritis.

Authors:  Alper Kirkpantur; Akif Altinbas; Mustafa Arici; Dilek Ertoy Baydar; Bulent Altun; Serap Arslan
Journal:  Clin Exp Nephrol       Date:  2007-12-21       Impact factor: 2.801

Review 7.  Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.

Authors:  Eng M Tan; Josef S Smolen
Journal:  J Exp Med       Date:  2016-09-12       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.